Endometrioid Ovarian Cancer Symptoms, Treatment & Care

What Is Endometrioid Ovarian Cancer?

Endometrioid ovarian cancer accounts for 10-15% of epithelial ovarian cancers. It is characterized by glandular cells that resemble the uterine endometrium and has a strong association with endometriosis. This cancer subtype often occurs alongside endometrioid endometrial cancer, with 15-20% of patients presenting with both cancers. Endometrioid ovarian cancer typically features mutations in CTNNB1 and ARID1A, distinguishing it from serous cancers that have TP53 mutations. Additionally, it tends to present less aggressively than clear cell ovarian variants. Women in their 50s to 60s are usually diagnosed at earlier stages, with approximately 60% of cases identified at stage I; however, grade 3 tumors can exhibit more aggressive behavior.

Symptoms and Signs of Endometrioid Ovarian Cancer

The symptoms of endometrioid ovarian cancer overlap with common ovarian cancer symptoms, including bloating, pelvic pain, early satiety, and postmenopausal bleeding, particularly if there is concurrent uterine involvement. A history of endometriosis, dyspareunia (painful intercourse), infertility, or abnormal uterine bleeding raises suspicion for this type of cancer. Masses related to endometrioid ovarian cancer may cause less dramatic pressure effects compared to mucinous cysts. In advanced cases, patients may experience ascites or bowel symptoms, but earlier detection is often achieved through gynecologic symptoms.

Causes and Risk Factors

• •History of Endometriosis
  Associated with 30-50% of endometrioid ovarian cancer cases.
• •Hormonal Factors
  Risk increases with unopposed estrogen exposure and the use of tamoxifen.
• •Genetic Predisposition
  Lynch syndrome involves mismatch repair deficiency in 10-20% of cases.
• •Molecular Mutations
  Unlike serous cancers linked to BRCA, these are associated with PTEN and PIK3CA mutations.
• •Lifestyle and Reproductive History
  Obesity and nulliparity contribute to risk, while oral contraceptives and tubal ligation provide protective effects.

Diagnosis and Staging

Elevated CA-125 levels typically lead to an ultrasound, which might reveal complex cystic-solid masses. An endometrial biopsy is performed to rule out synchronous uterine cancer. MRI scans can help differentiate between endometrioid tumors and benign endometriomas. Surgical staging, performed via laparotomy or laparoscopy, includes hysterectomy, salpingo-oophorectomy, omentectomy, and lymph node dissection according to FIGO guidelines. Immunohistochemistry testing (such as for MLH1/MSH2 loss) helps identify cases linked to Lynch syndrome, which is important for genetic counseling.

Treatment Options for Endometrioid Ovarian Cancer

Surgery can cure early-stage, low-grade disease (stage I, grade 1-2). For high-risk features, such as grade 3 tumors or stage II and higher, adjuvant chemotherapy (typically carboplatin and paclitaxel) is beneficial. Hormone therapy, including progestins, tamoxifen, and letrozole, is effective for estrogen receptor-positive (50-80% of cases) low-grade tumors. PARP inhibitors may be used for BRCA-like homologous recombination deficiency subsets, while immunotherapy targets cases with high microsatellite instability and Lynch syndrome. For young patients diagnosed with stage IA grade 1 cancer, fertility-sparing cystectomy is an option.

Get Your Free Cancer Diet Plan & Report Analysis Now on WhatsApp

Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.

Get My Free Plan on WhatsApp

India's First Cancer Care Management Platform

Free to start•Secure & private•No app download needed

Prognosis and Survival Rate

Understanding Survival Rates

The 5-year survival rate for stage I low-grade endometrioid cancer is excellent, exceeding 90%. This rate drops to between 60-80% for advanced stages, but endometrioid types tend to outperform serous types due to greater chemosensitivity. The median overall survival for this cancer can exceed 100 months, with recurrence patterns generally showing indolence that may favor hormonal control.

Factors Influencing Prognosis

Prognosis is better in cases that are low grade, at an early stage, have complete staging, exhibit favorable hormone receptor status, and demonstrate proficiency in mismatch repair. Patients with dual primaries or high-grade features have a poorer prognosis. Providing nutritional support can enhance adherence to hormonal therapy and improve surgical recovery.

Why Choose Everhope for Endometrioid Ovarian Cancer Care

Everhope Oncology offers integrated care with expertise in gynecologic pathology, enabling early detection of dual primaries. We provide hormone receptor profiling for personalized endocrine therapy and functional nutrition programs to counter estrogen-related metabolic effects. Screening for Lynch syndrome and comprehensive survivorship care are also prioritized to optimize long-term outcomes for this manageable subtype of ovarian cancer.